Cowen & Co. Reaffirms Their Hold Rating on Regeneron (REGN)

By Ryan Adsit

In a report released today, Yaron Werber from Cowen & Co. maintained a Hold rating on Regeneron (REGNResearch Report), with a price target of $353. The company’s shares opened today at $333.

According to, Werber is a 5-star analyst with an average return of 14.7% and a 66.3% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.

Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $420.80, implying a 26.4% upside from current levels. In a report released today, J.P. Morgan also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Regeneron’s market cap is currently $37.52B and has a P/E ratio of 16.16. The company has a Price to Book ratio of 4.28.

Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.